Corporate Profile

Cordlife Group Limited at a glance

Cordlife Group Limited ("Cordlife", together with its subsidiaries, the "Group") is a consumer healthcare company catering to the mother and child segment. Established in May 2001 and successfully listed on the Mainboard of Singapore Exchange Trading Limited ("SGX-ST") in 2012, the Group is one of the pioneers in the cord blood banking industry in Asia.

Cordlife is amongst the leading players for private cord blood banking services in all the markets it operates in, namely Singapore, Hong Kong, Malaysia, India, Indonesia and the Philippines. Inhabiting a distinctive niche in the healthcare industry, the Group is one of the foremost private cord blood banks to have gained a solid foothold in Asia. In the last 17 years, Cordlife has dedicated its undertakings to achieve market leadership in the industry. Having built a distinguished brand name, the Group continues to strive for excellence by means of support from its experienced management team, dynamic key executives along with its quality product and service offerings. Cordlife believes the Group has in place a strong foundation for future expansion.

The Group's processing and storage facilities in Hong Kong, India and Singapore are accredited by AABB, the world's gold standard in cord blood banking and its facilities in Indonesia and the Philippines are also ISO-certified. Cordlife Singapore achieved accreditation by FACT-Netcord, making it one of only six cord blood banks in the world to achieve accreditations from both AABB and FACT-Netcord simultaneously. . The Group’s majority owned Hong Kong and India subsidiaries, Hong Kong Screening Centre Limited (“HKSC”) and Cordlife Sciences (India) Pvt. Ltd. (“Cordlife India”), have also received accreditation from the College of American Pathologists (“CAP”), which is awarded to facilities that meet or exceed the highest standards in laboratory services. In July 2017, Cordlife Philippines became the first cord blood bank in the country to be accredited by AABB.

About Cordlife India

Cordlife India is a fully owned subsidiary of Cordlife Group Limited. The Indian Laboratory is AABB accredited and operates the most advanced umbilical cord and cord blood processing, testing and cryopreservation facility in the country, with a storage capacity of 150,000 cord blood units scalable by another few lakh units.

The state-of-the-art laboratory is equipped with the latest and the most modern equipment and has recently upgraded from the automated Sepax®2 to the FDA approved AXP®II. Its MNC (Mono Nuclear Cells) and CD34+ recovery rate is higher.^[1]

It maintains a clean-room infrastructure to ensure that stem cells are processed under the most sterile conditions. Located within a natural calamity proof building, the facility is also built with continuous power backup and round-the-clock surveillance system. Cordlife operates in more than 210 cities across India, making it one of the largest stem cell banking companies locally.

References:
1. Christy Kim et al. Meta-analysis of the AXP® and SEPAX® automated cord blood processing systems. CESCA Therapeutics White Paper; 2015.

About Corcell Bangladesh

Cordcell Bangladesh will mainly focus upon creating market awareness among all the expectant parents and their close relatives or friends. The business of Cordcell will be managed by a team of medical doctors, qualified pharmacist, bio technologist and genetic engineers. Their endeavour is to deliver international quality of healthcare services through its existing market of private hospitals, obstetricians and gynaecologists in Bangladesh. They will offer the service to collect cord blood and cord cell sample from Bangladesh and will ensure timely transportation of sample to Cordlife India for preservation. Cordcell Bangladesh will be local point of contact in Bangladesh for Cordlife Sciences India Pvt Ltd.